Evidence map›Paper›PMID 39805955›Full record

ArticleNature cancer2025

ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER

Jackson Liang, Xiaosai Yao, Patrick Aouad, Bu-Er Wang, Lisa Crocker, Subhra Chaudhuri, Yuxin Liang, Spyros Darmanis, Jennifer Giltnane, Heather M Moore and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jackson LiangDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Xiaosai YaoOncology Bioinformatics, Genentech, South San Francisco, CA, USA.
Patrick AouadDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6568-2151
Bu-Er WangDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Lisa CrockerTranslational Oncology, Genentech, South San Francisco, CA, USA.
Subhra ChaudhuriMicrochemistry, Proteomics, Lipidomics & Next Generation Sequencing, Genentech, South San Francisco, CA, USA.
Yuxin LiangMicrochemistry, Proteomics, Lipidomics & Next Generation Sequencing, Genentech, South San Francisco, CA, USA.
Spyros DarmanisMicrochemistry, Proteomics, Lipidomics & Next Generation Sequencing, Genentech, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4002-8158
Jennifer GiltnaneResearch Pathology, Genentech, South San Francisco, CA, USA.
Heather M MooreTranslational Medicine - Oncology, Genentech, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7098-3888
Junko AimiTranslational Medicine - Oncology, Genentech, South San Francisco, CA, USA.
Ching-Wei ChangBiostatistics, Genentech, South San Francisco, CA, USA.
Mary R GatesEarly Clinical Development, Genentech, South San Francisco, CA, USA.
Jennifer Eng-WongEarly Clinical Development, Genentech, South San Francisco, CA, USA.
Marc HafnerDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Ciara MetcalfeDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA. metcalfe.ciara@gene.com.ORCID http://orcid.org/0000-0001-7233-661X

Funding

Genentech (Genentech, Inc.) NA
6 · The paper itself

Abstract

Multiple next-generation molecules targeting estrogen receptor α (ERα) are being investigated in breast cancer clinical trials, encompassing thousands of women globally. Development of these molecules was partly motivated by the discovery of resistance-associated mutations in ESR1 (encodes ERα). Here, we studied the impact of ERα antagonist/degraders against Esr1 mutations expressed in mouse mammary glands. Inhibition of mutant ERα induced mixed-lineage cells, characterized by aberrant co-engagement of normally disparate master transcription factors. Lineage infidelity was also observed in Esr1-wild-type mice upon long-term estrogen deprivation. In ER

Indexed as

Breast NeoplasmsEstrogen Receptor alphaMutationAnimalsCell LineageCell Line, TumorCell ProliferationFemaleHumansMiceESR1 protein, humanEsr1 protein, mouseEstrogen Receptor alpha

Identifiers

PMID39805955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.